# The quality of medicines for the prevention and management of hypertensive disorders of pregnancy: A systematic review

**Authors:** Pooja Maharjan, Meghna Prasannan Ponganam, Pete Lambert, Joshua P. Vogel, Michelle McIntosh, Annie McDougall

PMC · DOI: 10.1371/journal.pgph.0002962 · PLOS Global Public Health · 2024-02-27

## TL;DR

This study reviews the quality of medicines used to manage pregnancy-related high blood pressure and finds widespread issues that could affect safety and effectiveness.

## Contribution

The study systematically reviews global quality data for eight essential medicines used in hypertensive disorders of pregnancy.

## Key findings

- Many medicines failed quality standards, including substandard active ingredients and contaminants.
- Issues were found in aspirin, calcium supplements, and antihypertensives across multiple countries.
- Poor-quality medicines raise concerns about safety and effectiveness in preventing maternal complications.

## Abstract

The quality of medicines for the prevention and management of hypertensive disorders of pregnancy globally is a critical challenge in the reduction of maternal mortality rate. We aimed to conduct a systematic review of available studies on the quality of the eight medicines recommended globally for the prevention and management of hypertensive disorders of pregnancy. We searched five electronic databases- Ovid MEDLINE, EMBASE, CINAHL, ProQuest and Cochrane Library, and also grey literature, without year or language limitations. Any study assessing the quality parameters (Active Pharmaceutical Ingredients, pH, sterility, solubility, impurities) of medicines by using any valid laboratory methods was eligible. Two reviewers independently screened the studies, extracted data and applied Medicine Quality Assessment Reporting Guidelines tool for quality assessment. Results were narratively reported and stratified by the drug types. Of 5669 citations screened, 33 studies from 27 countries were included. Five studies reported on the quality of magnesium sulphate—two (Nigeria and USA) found substandard medicine due to failing API specification and contaminants, respectively. Another study from Nigeria and a multi-country study (10 lower-middle- and low-income countries) found poor-quality due to failing the pH criteria. Seven of eight studies evaluating aspirin found quality issues, including degraded medicines in five studies (Brazil, USA, Yugoslavia and Pakistan). Five studies of calcium supplements found quality issues, particularly heavy metal contamination. Of 15 antihypertensives quality studies, 12 found substandard medicines and one study identified counterfeit medicines. This systematic review identified pervasive issues of poor-quality medicines across all recommended medicines used to prevent or treat hypertensive disorders of pregnancy, raising concerns regarding their safety and effectiveness.

## Linked entities

- **Chemicals:** magnesium sulphate (PubChem CID 24083), aspirin (PubChem CID 2244)

## Full-text entities

- **Diseases:** hypertensive disorders of pregnancy (MESH:D046110)
- **Chemicals:** aspirin (MESH:D001241), heavy metal (MESH:D019216), calcium (MESH:D002118), magnesium sulphate (MESH:D008278)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10898726/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC10898726/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC10898726/full.md

---
Source: https://tomesphere.com/paper/PMC10898726